



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**15 March 2019**

---

## **EXECUTIVE CHAIRMAN – EXTENSION OF APPOINTMENT – MATERIAL CONTRACT TERMS**

Bionomics Limited (ASX: BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company announced on 15 November 2018 that Dr Errol De Souza would take up the role of Executive Chairman from 12 November 2018 expiring on 31 March 2019, the material terms of that appointment as set as out in the ASX Announcement of 15 November 2018.

The Company has agreed to extend the term of Dr De Souza's appointment to 30 June 2019 on the same terms and conditions, a summary of which are as follows:

### **Material Terms of Extended Consultancy Agreement – Executive Chairman**

In accordance with ASX Listing Rule 3.16.4, Bionomics makes the following disclosures in respect of the material terms of the Consulting Agreement between the Company and Dr Errol De Souza dated 15 November 2018:

|                                   |   |
|-----------------------------------|---|
| <b>Position</b>                   | Executive Chairman                                |
| <b>Commencement Date</b>          | 12 November 2018                                  |
| <b>Expiry Date</b>                | 30 June 2019                                      |
| <b>Fixed Remuneration</b>         | \$18,000 per month, for 10 working days per month |
| <b>Short Term Incentive (STI)</b> | Not applicable                                    |
| <b>Long Term Incentive (LTI)</b>  | Not applicable                                    |
| <b>Termination</b>                | 7 days' notice by either party                    |

### **FOR FURTHER INFORMATION PLEASE CONTACT:**

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
+61 8 8354 6181  
[jmoschakis@bionomics.com.au](mailto:jmoschakis@bionomics.com.au)

### **About Bionomics Limited**

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a

strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

[www.bionomics.com.au](http://www.bionomics.com.au)